43 completed, 8 unknown, 3 terminated, 1 active not recruiting. 56 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 56 | Completed 43, Unknown 8, Terminated 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 4, Unknown 2, Active not recruiting 1 |
Follow Dermatomycoses: new trials by email Literature Review of Dermatomycoses trials Research Report on Dermatomycoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution Working Amphotericine in liposome (Ambisome®) - Tinea Capitis | Phase 2 / Phase 3 | Active not recruiting | Sohag University | 30 | 2025-04-01 | 2025-05-20 |
| Efficacy and Safety of Terbinafine and Itraconazole Terbinafine Tablets, Itraconazole - Tinea Corporis, Tinea Cruris | Phase 2 / Phase 3 | Unknown | Dhaka Medical College | 150 | 2023-05-01 | 2023-05-31 |
| Use of Essential Oils as Natural Therapies application of cream "La Chinata" - Dermatophytoses, Skin Lesion | Phase 3 | Completed | University of Extremadura | 49 | 2023-02-11 | 2023-12-15 |
| A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) MOB015B, Vehicle (Placebo Comparator) - Onychomycosis | Phase 3 | Unknown | Moberg Pharma AB | 350 | 2022-05-09 | 2024-06-26 |
| Efficacy of Intralesional PRP in Treatment of Onychomycosis intralesional platelet rich plasma, Oral terbinafine - Platelet Rich Plasma | Phase 3 | Unknown | Sohag University | 75 | 2021-12-01 | 2021-11-22 |
| Comparison of Efficacy of Double Dose Oral Terbinafine Vs Itraconazole in Treatment of Dermatophyte Infections of Skin. Terbinafine Pill, Itraconazole capsule - Dermatophyte Infection, Terbinafine Adverse Reaction | Phase 3 | Completed | Pak Emirates Military Hospital | 120 | 2021-03-15 | 2022-04-01 |
| A Therapeutic Equivalence Study of Ketoconazole Cream 2% Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.) - Tinea Pedis | Phase 3 | Completed | Douglas Pharmaceuticals America Ltd | 682 | 2019-12-11 | 2020-08-06 |
| Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis Candicort®, Nizoral®, Baycuten N® - Tinea | Phase 3 | Completed | Ache Laboratorios Farmaceuticos S.A. | 125 | 2019-06-11 | 2021-09-20 |
| Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole SUBA itraconazole, Conventional itraconazole - Invasive Fungal Infections | Phase 2 / Phase 3 | Completed | University of Alabama at Birmingham | 88 | 2018-09-17 | 2023-07-07 |
| Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo - Tinea Pedis | Phase 3 | Completed | Encube Ethicals Pvt. Ltd. | 831 | 2018-08-23 | 2019-06-27 |
| Non-inferiority Trial of Dapaconazole Versus Ketoconazole Dapaconazole, Ketoconazole - Tinea Pedis | Phase 3 | Completed | Biolab Sanus Farmaceutica | 360 | 2017-11-01 | 2020-07-27 |
| Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Efinaconazole Topical - Onychomycosis | Phase 3 | Completed | Western University of Health Sciences | 40 | 2017-06-06 | 2020-10-30 |
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Ibrexafungerp - Invasive Candidiasis, Mucocutaneous Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 233 | 2017-04-01 | 2024-11-20 |
| Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Nailner 2 in 1, Ciclopirox 8% - Onychomycosis | Phase 3 | Unknown | MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA | 46 | 2017-04-01 | 2017-03-31 |
| Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis Dapaconazole, Ketoconazole - Tinea Pedis | Phase 3 | Withdrawn | Biolab Sanus Farmaceutica | 2016-06-01 | 2017-02-01 | |
| Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Econazole Nitrate Cream, 1%, Placebo - Tinea Pedis | Phase 3 | Completed | Mylan Inc. | 876 | 2016-03-15 | 2022-03-07 |
| Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis P-3058 10%, vehicle of P-3058 10%, amorolfine 5% - Onychomycosis | Phase 3 | Completed | Polichem S.A. | 953 | 2015-08-20 | 2018-09-26 |
| Design and Clinical Evaluation of a School Meal With Deworming Properties Ujiplus, Albendazole, uji - Helminthiasis, Tinea Capitis | Phase 2 / Phase 3 | Completed | Kenya Medical Research Institute | 326 | 2015-05-01 | 2016-09-07 |
| BE Study of Naftifine HCL Naftifine hydrochloride 2%, Placebo, Naftin® 2% (Naftifine hydrochloride 2%) - Tinea Pedis | Phase 3 | Completed | Genzum Life Sciences | 693 | 2015-03-01 | 2017-05-11 |
| Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population P-3058 - Onychomycosis | Phase 3 | Completed | Polichem S.A. | 20 | 2014-08-01 | 2018-03-08 |
Showing 20 of 56. Sign in to see all of them.
Onychomycosis (21) · Tinea Pedis (19) · Mycoses (6) · Tinea (6) · Tinea Cruris (6) · Foot Dermatoses (5) · Tinea Capitis (5) · Blastomycosis (4) · Histoplasmosis (4) · Coccidioidomycosis (2) · Keratoderma, Palmoplantar, Epidermolytic (2) · Nails, Malformed (2) · Onycholysis (2) · Twenty-Nail Dystrophy (2)
Bacterial Infections and Mycoses (56) · Infections (56) · Skin Diseases (56) · Skin and Connective Tissue Diseases (56) · Skin Diseases, Infectious (55) · Mycoses (50) · Tinea (45) · Foot Diseases (23) · Pathological Conditions, Signs and Symptoms (23) · Nail Diseases (21) · Foot Dermatoses (19) · Signs and Symptoms (19) · Pruritus (18) · Skin Manifestations (18)
Terbinafine (10) · Itraconazole (5) · Ketoconazole (4) · naftifine (4) · 1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (2) · Clotrimazole (2) · Gels (2) · Solutions (2) · Albendazole (1) · Amphotericin B (1) · Calcium Dobesilate (1) · Fluconazole (1) · Griseofulvin (1) · Liposomes (1) · amorolfine (1)
Merz North America, Inc. (5) · Medicis Global Service Corporation (3) · Novartis (3) · Novartis Pharmaceuticals (3) · Pfizer (3) · AmDerma (2) · Biolab Sanus Farmaceutica (2) · Dow Pharmaceutical Sciences (2) · Polichem S.A. (2) · Promius Pharma, LLC (2) · Sohag University (2) · Ache Laboratorios Farmaceuticos S.A. (1) · Bayer (1) · Celtic Pharma Development Services (1) · Dhaka Medical College (1)
United States (35) · Canada (7) · Belize (6) · Germany (6) · Puerto Rico (6) · Brazil (4) · Dominican Republic (4) · Honduras (4) · Poland (4) · Spain (4) · Iceland (3) · Belgium (2) · Czechia (2) · Egypt (2) · El Salvador (2)
Lawrence Parish, MD (3) · Ron Staugaard (3) · Daniel Piacquadio, MD (2) · Joanne Fraser, PhD (2) · Kent Allenby, MD (2) · Maurizio Caserini, MD (2) · Andrej Spec, MD (1) · Bernard Goffe, MD (1) · David M Harris, PhD (1) · Dr. Umar Abdul Ali Qureshi, MBBS (1)
PMID 25007364, PMID 21968664, PMID 22052309, PMID 23884486, PMID 30526582, PMID 32457106, PMID 38440302
2008 (1), 2015 (1), 2017 (1)